(2)
PUNE, India, Dec. 17, 2020 /PRNewswire/
The UV cured resins market was valued at US$ 3662.24 Mn in 2019 and is anticipated to witness a compound annual growth rate of 8.9% over the forecast period.
The outbreak of the covid-19 is positively influencing the growth of global UV cured resins market. UV curable resins enhances the adhesive strength and showcases exceptional compatibility with metals, plastics and other materials. The specific property is incrementing its demand across medical industries, for manufacturing of products in high volumes.
Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request sample.php?id=750
The rising adoption of digitization among manufacturers to connect with clients directly rather than depending upon intermediaries is influencing the adoption direct online channels among UV cured resin manufactures, thereby, contributing to the growth of the market across the globe.
Chipscreen and HISUN reach a strategic cooperation
News provided by
Share this article
Share this article
SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation. CHIPSCREEN BIOSCIENCES will exclusively grant HISUN PHARMACEUTICAL the right to promote Bilessglu® (Chiglitazar Sodium tablets), independently developed and manufactured by its wholly-owned subsidiary CHENGDU CHIPSCREEN PHARMACEUTICAL CO., LTD., in 19 provinces and regions in China. This cooperation intends to quickly provide to Chinese patients with this innovative diabetes treatment mechanism. CHIPCREEN BIOSCIENCES remains as the owner and manufacturer of the drug. Dr. Lu Xianping, Chairman of CHIPCREEN BIOSCIENCES, and Mr. Li Yan, President of HISUN PHARMACEUTIC